The therapeutic landscape of NSCLC has been transformed by the discovery of recurrent, targetable genomic alterations—most commonly involving EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, and NTRK genes—together with the emergence of immune-checkpoint inhibitors guided by PD-L1 expression and tumor mutational burden (TMB) [5,6,7]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.